Tabalumab, an anti-BAFF monoclonal antibody, showed efficacy and safety in rheumatoid arthritis in phase two studies but did not meet the primary or secondary outcomes in a phase three study (41), and Belimumab, a biologic BAFF inhibitor, has been the first biologic agent licensed for Lupus therapy (35). Here, TNFSF13B is linked to rheumatoid arthritis.